Endocrine Abstracts

Objective: After Cushing Syndrome (CS) is cured, up to 70% of patients develop chronic adrenal insufficiency (AI) and hypothalamus-pituitary-adrenal (HPA) axis dysfunction. A long-term treatment with glucocorticoids (GC) is mandatory to overcome AI. However, this treatment implies non-desired complications. Fibroblast growth factor (FGF21), a key regulator of metabolism, has a bidirectional relationship with GC that bypasses the negative feedback of the HPA axis. In this study...

Background: Long-term studies evaluating mortality in patients with non-functioning (NF) pituitary tumors (PitNets) are limited, although standardized mortality ratios (SMR) in these patients are reported to be higher than that of general population. There is also no agreement on predictive factors associated to the increased mortality apart from age at diagnosis and glucocorticoid substitution therapy dose.Objective: To assess long-term mortality and as...